Atacicept is a dual anti-BAFF/APRIL fusion protein currently in clinical development for treatment of IgA nephropathy (IgAN). Better understanding vaccine response and immunity with atacicept, especially to COVID-19, may help assess atacicept's benefit risk profile. Atacicept has been studied in IgAN in the Phase 2a JANUS study, which measured tetanus and diphtheria vaccine titers up to 72 weeks, and the Phase 2b ORIGIN study, where impact of atacicept on COVID-19 infection rates and severity could be assessed.
No takes yet. Share an insight, caveat, or question.
Barratt et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: